The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Perspectives

Tackling prosthetic heart valve-related deterioration: Liège translational cardiovascular research programme

EuroIntervention 2020;15:1485-1487. DOI: 10.4244/EIJV15I17A272

1. University of Liège Hospital, GIGA Cardiovascular Sciences, Department of Cardiology, CHU Sart Tilman, Liège, Belgium; 2. National Fund for Scientific Research (F.R.S.-FNRS), Brussels, Belgium


The use of medical devices (MDs) has impacted positively on quality of life and survival. Prosthetic heart valves (PV) are among the most implanted blood-contacting MDs. About four million heart valve replacements have been performed over the past 50 years, and this remains the only definitive treatment for most patients with severe valvular heart disease. About 300,000 PV implantations are performed every year worldwide; the total number of valve replacements is projected to be 850,000 per year by 20501. With the advent of transcatheter aortic valve implantation (TAVI), these figures are expected to increase even more. Two types of PV are in use ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Outcomes in nonagenarians undergoing transcatheter aortic valve implantation: a nationwide analysis